InsidersTradesSigma
Total declarations
Companies
▲ Purchases (0 ops.)
▼ Sales (13 ops.)
Insider track record
CEODisclosed buys
0
Disclosed sells
13
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Venker Eric, Chief Executive Officer. Officer active across 2 companies, notably Immunovant, Inc.. In total, 65 disclosures have been recorded. Breakdown: 0 buy · 13 sells. Total volume traded: €1.8m. History available since 25 March 2022. The latest transaction was disclosed on 1 July 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations65 total
92,188 shares@ US$14.46Common StockSEC:0001764013-26-000077:0
86,629 shares@ US$38.14Common StockSEC:0001764013-26-000077:1
3,092 shares@ US$38.48Common StockSEC:0001764013-26-000077:2
368,750 shares@ US$14.460.082% mcap50.0% of flowCommon StockSEC:0001764013-26-000024
368,750 shares@ US$14.460.082% mcap50.0% of flowCommon StockSEC:0001764013-26-000024:0
39,148 shares@ US$11.042.5% of flowCommon SharesSEC:0001140361-25-020241:0
10,945 shares@ US$10.150.6% of flowCommon SharesSEC:0001140361-25-014986:0
10,945 shares@ US$10.970.7% of flowCommon SharesSEC:0001140361-25-010120:0
100,000 shares@ US$3.852.4% of flowCommon SharesSEC:0001140361-25-005717:0
300,000 shares@ US$3.857.4% of flowCommon SharesSEC:0001140361-25-004951:0
8,682 shares@ US$11.150.6% of flowCommon SharesSEC:0001140361-25-001662:0
250,000 shares@ US$3.856.1% of flowCommon SharesSEC:0001140361-24-050723:0
10,945 shares@ US$11.570.8% of flowCommon SharesSEC:0001140361-24-050458:0
10,945 shares@ US$11.490.8% of flowCommon SharesSEC:0001140361-24-047697:0
10,945 shares@ US$11.920.8% of flowCommon SharesSEC:0001140361-24-043962:0
10,945 shares@ US$11.970.8% of flowCommon SharesSEC:0001140361-24-041786:0
10,947 shares@ US$11.480.7% of flowCommon SharesSEC:0001140361-24-038306:0
204,000 shares0Common SharesSEC:0000950103-24-011229:0
10,945 shares@ US$11.000.7% of flowCommon SharesSEC:0001140361-24-034282:0
10,945 shares@ US$10.800.7% of flowCommon SharesSEC:0001140361-24-031174:0
16,003 shares@ US$11.371.1% of flowCommon SharesSEC:0001140361-24-027208:0
16,002 shares@ US$10.461.0% of flowCommon SharesSEC:0001140361-24-021492:0
16,003 shares@ US$10.011.0% of flowCommon SharesSEC:0001140361-24-014896:0
16,002 shares@ US$11.541.1% of flowCommon SharesSEC:0001140361-24-009099:0
96,950 shares@ US$3.852.3% of flowCommon SharesSEC:0001140361-24-006833:0
25 of 65 declarations
About Venker Eric
Public sources indicate that Eric Venker, M.D., Pharm.D., is President of Roivant Sciences and Chief Executive Officer of Immunovant. Immunovant says he has served on its Board of Directors since 2020, and an SEC filing states that he was appointed Immunovant’s Chief Executive Officer on April 18, 2025, effective April 21, 2025. Roivant and Immunovant also say he previously served as a physician at NewYork-Presbyterian Hospital, Columbia University Medical Center, where he trained in internal medicine. Sources: https://www.roivant.com/about/leadership
